CXCL10 As a Biomarker Of ILD in Patients WithRA

Not Applicable

• Conditions: Interstitial Lung Disease in Patients With Rheumatoid Arthritis
• Interventions: Diagnostic Test: serum cxcl10 by ELISA

• Registration Number: NCT04356066
• Lead Sponsor: Assiut University

Brief Summary

Rheumatoid arthritis is a chronic inflammatory disease that affects the joints, causing symmetric pain, stiffness, swelling, and limited motion and function of multiple joints, its fibro inflammatory manifestations may develop in other organs.

Detailed Description

Rheumatoid arthritis is complicated by lung manifestations, such as interstitial lung disease which is the most common cause of morbidity and mortality in rheumatoid arthritis patients. Rheumatoid arthritis-interstitial lung disease is a progressive fibrotic disease of the lung parenchyma that includes a broad spectrum of disorders such as nonspecific interstitial pneumonia, usual interstitial pneumonia , desquamative interstitial pneumonia, cryptogenic organizing pneumonia, diffuse alveolar damage, acute interstitial pneumonia, and lymphocytic interstitial pneumonia . Rheumatoid arthritis-interstitial lung disease in which available data indicate that dysregulated inflammatory cascades can elaborate a host of cytokines, chemokines, and growth factors that collectively promote epithelial and endothelial cell damage, angiogenesis, fibroblast differentiation/proliferation, and lung fibrosis . Given the clinical implications of putative signaling cascades involved in these processes, biomarkers that can be used to clarify disease pathogenesis and identify factors governing disease progression are clearly needed .

Study Timeline

• Status Verified: 2020-01
• Study First Submitted: 2020-01-17
• Study First Submitted QC: 2020-04-20
• Last Update Submitted: 2020-04-20
• Study First Posted: 2020-04-22
• Last Update Posted: 2020-04-22
• Study Start: 2020-12-19
• Primary Completion: 2021-01-19
• Study Completion: 2022-01-19

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

1. Adult rheumatoid arthritis patients who fulfilled the 2010 American College of Rheumatology/European league against rheumatism criteria for the classification of Rheumatoid Arthritis.
2. Adult rheumatoid arthritis patients with interstitial lung disease.

Exclusion Criteria

1. Individuals with other autoimmune diseases (systemic lupus erythematosus, polyarteritis nodosa, dermatomyositis, scleroderma, spondyloarthritis and inflammatory bowel disease).
2. Individuals with hepatitis, Rhinovirus infection, cerebral malaria.
3. Individuals with colorectal carcinoma, syndrome of frailty, vetiligo.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Adult Rheumatoid Arthritis Patient with Interstitial Lung Dise	serum cxcl10 by ELISA	* History taking: age, sex, disease duration, history of present illness, drug intake, past and family history. * Physical examination including thorough clinical examination. * Health assessment questionnaire-disability index (HAQ-DI): It is used as a subjective measure of physical function of RA patients (Pincus et al., 1983). There are 20 items in 8 categories: dressing, rising, eating, walking, hygiene, reach, grip, and usual activities (Jessica et al., 2018).

Primary Outcome Measures

Name	Time	Method
CXCL10 As a Biomarker Of Interstitial Lung Disease in Patients With Rheumatoid Arthritis	2 years	serum level